2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsSpecific molecular alterationsNovel animal modelInnate immune systemCheckpoint inhibitorsImmune dysregulationMDS patientsClinical trialsNovel therapiesTherapeutic strategiesAnimal modelsGermline predispositionImmune systemMolecular alterationsClinical researchInternational ConsortiumNeoplasmsClinical workGenetic landscapeInternational WorkshopPatientsCurrent landscapePathogenesisTherapyDisease
2020
Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia
Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. Current Cancer Drug Targets 2020, 20: 473-489. PMID: 32357813, DOI: 10.2174/1568009620666200502011059.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAntibodies, MonoclonalAntigens, NeoplasmAntineoplastic Agents, ImmunologicalCancer VaccinesHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveKiller Cells, NaturalLeukemia, Myeloid, AcuteReceptors, Chimeric AntigenT-Lymphocytes, CytotoxicTransplantation, HomologousTumor EscapeConceptsAcute myeloid leukemiaTumor-associated antigensImmune systemAML cellsMyeloid leukemiaTreatment of AMLAllogeneic stem cell transplantationEffective immunotherapeutic strategiesNatural killer cellsStem cell transplantationHumoral immune reactionsCell-based therapeutic approachesSurface receptor expressionAcute leukemia cellsDirect immunosuppressionImmunotherapeutic strategiesTreatment landscapeImmunotherapeutic approachesCellular immunotherapyKiller cellsCell transplantationClinical managementHematologic malignanciesReceptor expressionDecreased immunogenicity
2016
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors
Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy 2016, 8: 767-774. PMID: 27349976, DOI: 10.2217/imt-2016-0040.Peer-Reviewed Original ResearchConceptsMyeloid-derived suppressor cellsInnate immune cellsCheckpoint inhibitorsSuppressor cellsImmune cellsMast cellsImmune checkpoint inhibitorsAntitumor immune responseImmune cell numbersReceptor tyrosine kinase KITDurable responsesMelanoma patientsClinical benefitTyrosine kinase KITCancer patientsPreclinical dataPoor survivalImmune responseSuppressive componentsImmune systemKIT inhibitorsTumor microenvironmentAntitumor activityKinase KITRecent evidence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply